John Stone reports that 42% of patients maintained treatment-free remission after 1 year of weekly tocilizumab in part 2 of the GiACTA trial. GC exposure over 3 years also lower #EULAR2019 #GiantCellArteritis https://t.co/XpFyRj9wrx